7\ D			
AD			

Award Number: DAMD17-94-J-4327

TITLE: Breast Cancer Screening by Physical Examination:

Randomized Trial in the Philippines

PRINCIPAL INVESTIGATOR: D.M. Parkin, M.D.

CONTRACTING ORGANIZATION: International Agency for Research on

Cancer

69372 Lyon Cedex 08 France

REPORT DATE: October 2001

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank	. AGENCY USE ONLY (Leave blank) 2. REPORT DATE 3. REPORT TYPE AND DATES COVERED					
	October 2001	Annual (30 Sep 00				
4. TITLE AND SUBTITLE			FUNDING N			
Breast Cancer Screening		on:	AMD17-94-	-J-4327		
Randomized Trial in the	e Philippines	1				
6. AUTHOR(S)						
D.M. Parkin, M.D.						
7. PERFORMING ORGANIZATION N		8.		G ORGANIZATION		
International Agency fo			REPORT NUMBER			
69372 Lyon Cedex 08 Fra	ance					
E-Mail: parkin@iarc.fr						
· · · · · · · · · · · · · · · · · · ·		İ				
9. SPONSORING / MONITORING A	GENCY NAME(S) AND ADDRESS(ES	5) 10). SPONSORI	NG / MONITORING		
			AGENCY R	EPORT NUMBER		
U.S. Army Medical Research and	Materiel Command	1				
Fort Detrick, Maryland 21702-50	012	1				
		•				
11. SUPPLEMENTARY NOTES		•				
12a. DISTRIBUTION / AVAILABILITY	STATEMENT		, tour	12b. DISTRIBUTION CODE		
Approved for Public Rel	lease; Distribution Unl	imited				
13. ABSTRACT (Maximum 200 Woi	-d-l					
Completed activities. 1) continuing ide	ous) entification and registration of new hre	east cancer in the resident non-	ulation with co	ellection of clinical details of stage		
at diagnosis; incidence data have bee	en completed for years 1995-1998. 2)	continuing identification and re	egistration of a	Il cases of malignant cancer in		
the resident population: 3) continuing	collection and processing of death cer	rtificates (all causes); 4) record	linkage betw	een files of incident cases and		
master files of the intervention cohort; 5) selection of controls matched to incident cases in the cohort and analysis of the risk of breast cancer associated						
with reproductive variables.						
	1.1.1		ing details of in	tan antian files):		
Updated summary of the status of the databases upgraded during follow-up phase (see previous reports for details of intervention files):						
Master file: Nominal list of all women	Master file: Nominal list of all women interviewed and offered PE. Includes 10% who refused PE 154,000 Intervention population lists: Lists of the eligible population resident in the intervention HCs in the years when the intervention was conducted 218,928					
Control population lists: Lists of the	eligible population resident in the cont	rol HCs in the years when the	intervention w	as conducted. 191,086		
Clinical follow up of women positive at	PE: Outcome of referral and of clinic	al investigation		3,492		
Incident breast cancer cases: Incider	ice completed for years 1995-1998.					
In addi	tion 85% of incident cases in 1999 an	d 50% of cases incident in 200	00.	3,300		
Incidence of all malignant neoplasms:	Incident cases of all malignant neop	plasms have been completed to	or years 1995	-1997 4,800 123 cases		
Nested case-control study: Case-con	trol study of risk factors for breast can	cer nested in the intervention of	conort.	978 controls		
				270 00111010		
On-going Cancer registry follow-up pro	ocedures have been established and	breast cancer cases are record	ded regularly.	Clinical details of stage at		
diagnosis are sought systematically for	or all cases. Death certificates (all caus	ses) of women resident in Meti	ro Manila are	collected regularly.		
14. SUBJECT TERMS			1	15. NUMBER OF PAGES		
			-	18 16. PRICE CODE		
17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICA OF ABSTRACT	TION	20. LIMITATION OF ABSTRACT		
Unclassified	Unclassified	Unclassified	d l	Unlimited		

(3) TABLE OF CONTENTS

	Page
Front page	1
SF 298 Report Documentation Page	2
Table of contents	3
Introduction	4
Body	6
Key research accomplishments	12
Reportable outcomes	12
Conclusions	13
Tables	14-17
References	18

Grant DAMD17-94-J-4327 4

(4) INTRODUCTION

In 1990 breast cancer accounted for 795,000 new cases per year (Ferlay *et al.*, 1998), and it was the most frequent cancer in women. Incidence rates are still rising in many countries, particularly in the developing world (Coleman *et al*, 1993). It seems that these trends are likely to continue, since the current pattern of later childbearing, decreasing fertility, and 'westernization' of diets will all be associated with increased risk.

At present, our knowledge of environmental risk factors does not permit formulation of any practical primary prevention programs. The introduction of adjuvant therapy with Tamoxifen has improved survival of older cases and a decline of mortality from breast cancer below age 50, observed in some high-risk countries, has also been attributed to adjuvant therapy (Nab *et al.*, 1994, Olivotto *et al.*, 1994). However, further improvements in surgical techniques, or in radiotherapy, are very unlikely to provide more than marginal changes in mortality rates.

A much greater decrease in deaths from breast cancer is achievable through screening programs which lead to detection of cancers which are smaller, at an earlier stage, and less malignant than those which surface clinically. Several randomized trials of screening for breast cancer have been carried out; in the majority the screening modality used was mammography, with or without physical examination of the breasts. There is a clear consensus that such screening programs are capable of decreasing the risk of mortality from breast cancer in women aged 50 or older (Miller et al., 1990; Day, 1991; Moss, 1996). The efficacy of mammography in women below 50 is still a very controversial issue resulting in contradictory recommendations and policies (Moss,1996; Nelson, 1997). At best, mortality reduction in this age group would be only 15% or one-half that of older women (based on meta-analyses of randomized trials). The reason of lower efficiency of mammography in younger women is not clear; possible causes are cancers growing faster in these ages or sensitivity of mammography in the pre-menopausal breast being relatively low.

Population screening programs which depend upon mammography require extensive provision of expensive technology and highly trained radiologists and radiographers. The cost per life-year saved is therefore relatively high (Barnum and Greenberg, 1991), and clearly an inappropriate use of health care resources for many countries (WHO, 1984).

The alternative screening strategies which have been proposed are physical examination of the breasts (PE), and breast self-examination (BSE). Short-term results of a large scale trial of BSE among 300,000 textile workers in Shanghai, China, conducted by researchers of the University of Washington have been recently published (Thomas *et al.*, 1997). Biases such as low compliance with the intervention, failure of proper randomization or low proficiency in performing BSE could be confidently excluded. No significant reduction of breast cancer mortality in the intervention group has been detected after 5 years of follow-up and the distribution of stage at diagnosis in screen and control groups were very similar. As discussed by the Authors, both results are not definitive; even in trials of mammography a reduction of mortality appeared only after 5 years from entry into the study and stage at diagnosis, which is assessed retrospectively, may well be affected by a rate of mis-classification which can obscure existing differences in the intervention and control groups.

Nevertheless, the small size of the lesions diagnosed in the control subjects in this trial (47 % ≤2 cm diameter) suggests a high level of health-awareness in the Shanghai population, and may give little scope for improvement in outcome through early detection by BSE.

At present PE has never been used as the sole modality of screening, so that its effectiveness is not known. Indirect evidence based on estimates of the accuracy of PE relative to mammography suggests that this type of examination could reduce mortality rates by 2/3 to 3/4 of that achievable by mammography screening in women aged 50 or more. PE alone may be effective in younger women, among whom up to 25% cancers are missed by mammography; in addition, there is evidence that PE improves the performance of mammography. The working group who reviewed in 1979 the results of the Breast Cancer Detection Demonstration Project, the first large nonexperimental evaluation of mammography, stated that high priority should be given to the evaluation of PE as a single screening modality. The recommendation was not followed by action until the project described here, possibly because of the rapid spreading of mammography in most developed countries which vitiated the feasibility of an unscreened control group.

The purpose of the present work was to establish 1) whether a program of mass screening by PE performed by trained paramedical personnel could be set up in a developing country as part of the routine activity of first level health services, and 2) whether and to what extent such a program could reduce mortality from breast cancer. The location is Metro Manila and Rizal Province of the Philippines. This population has a relatively high incidence of breast cancer, considerably above that of other Asian populations, and comparable to that in southern Europe.

Grant DAMD17-94-J-4327 6

(5) **BODY**

The study is a randomized controlled trial of the effect of annual physical examination (PE) of the breasts performed by trained nurses/midwives, in reducing mortality from breast cancer. The study area comprises the central, more urbanized municipalities of the National Capital Region (Districts I, II, III and IV), which includes 12 municipalities each having municipal health centers in the township area and barangay health stations in more rural areas. In 1990, the estimated size of the female population aged 35-64 was about 340,000. The units of randomization are health centers (HCs) within the selected municipalities of the Manila - Rizal area.

Women aged 35-64 years resident in the intervention HC areas were offered annual breast examinations, carried out by specialized midwives/nurses. At the first visit, these women were also instructed in the technique of breast self-examination (BSE) and provided with a leaflet in the local language explaining the purpose and methodology of BSE.

Women in the control area received no active intervention, but were exposed to the general health education campaigns carried out by municipal authorities and voluntary bodies.

The examiners were trained using a program already developed and tested in the Philippines, making use of breast silicon models. Training was repeated for selected groups of examiners with detection rates markedly above or below the mean. Women eligible for screening were invited to participate through a variety of mechanisms but mainly by home visits.

At the first visit women were interviewed to record demographic variables and risk factors for breast cancer. Instruction in BSE was given and PE performed. Demographic characteristics of women who refused PE were also recorded.

Women with detected abnormalities were referred for final diagnosis to special clinics, made available in 3 major hospitals staffed by project personnel. After one year of intervention, compliance with referral was only 21% and all remedies put in place to improve it (see below), did not significantly affect the proportion of positive women who reached a definitive diagnosis. The intervention was therefore discontinued after the completion of the first round and follow-up of the intervention and control cohorts has been undertaken.

The follow-up phase is on-going. In this report we present some early results of the outcome of the intervention and the first analysis of risk factors for breast cancer in this population, based on data collected during the intervention.

Results

A) Intervention

During 1995 a coordinating center was set up. Two hundred and two Health Centers were randomized to intervention and control arms. Hospital clinics for referral of positive women and mechanisms for documentation of results were established.

Personnel from the intervention HCs were recruited and trained. It soon became evident that the regular personnel of HCs could not reach the scheduled rate of 14,000 woman-examinations per month. Therefore, nurses were recruited to work full-time for the project (FTNs). In March 1996, the intervention reached a regular pace. The first round of the intervention was completed in December 1997. The results of the intervention after completion of the single round of examinations, are summarized in Table 1. Three-thousand four hundred and ninety two women were detected positive for a lump at first examination. Of these, 42.3% actively refused further investigation, 21.8% who did not report to the tumor clinics had moved away or died when visited at home and seventy-one cases (2%) are waiting for final diagnosis. Only 32% (1,110 women) completed the diagnostic process, of these 33 were malignant cancers detected.

Comparison of characteristics of compliers and refusers.

In the annual report of 1997 we presented an analysis of the characteristics of a sample of women who accepted PE and of those who refused it. The two groups do not differ by age, prevalence of smoking or compliance with screening for cervix cancer, the latter being an indication of general attitude towards preventive practices. In contrast with what is observed in western countries, refusers are of higher social class, as indicated by greater average income and significantly lower parity.

Interview of a sample of 999 women resident in the control area (years 1999-2000).

A sample of 2,000 names, stratified by age, was drawn from the file of the eligible population in the control HCs. Two interviewers were recruited and trained to trace and perform interviews according to the questionnaire used in the intervention phase. Interviewers were provided with many more suitable names to allow for the turn-over of the resident population (migrated or deceased). The target number was 1,000. The purpose of this sample survey is to estimate the actual proportion of the control cohort that is present in 1999, and to compare the characteristics of this cohort with those of the intervention group as a check on the randomization procedure. Thirty eight percent of the women in the original lists of resident population could not be traced. Nine-hundred and ninety nine interviews were completed.

Table 3 shows a comparison of some characteristics of women in the intervention area, examined (compliers) or interviewed but refused examination (refusers), with the 999 resident in the control area who were successfully traced. The table shows that the latter group is of similar age at interview and age at menarche compared to the others. Control women however, show lower age at first birth, a higher proportion of them is parous and a significantly greater proportion drinks alcohol regularly.

Action taken to improve compliance with clinical investigation among women detected positive.

One thousand women who were positive for a lump at the initial visit but who had not subsequently turned up at a referral clinic were visited a second time to assess the motives for non-compliance. The survey indicates that the main reasons for non-compliance are inconvenience and costs. In order to induce greater motivation to seek

medical attention, medical teams formed by a doctor and a nurse and equipped to perform needle biopsies, were sent to visit non-compliers at home in order to obtain a final diagnosis. This activity commenced in March 1997 (recruitment and training of doctors) and was completed by end of April 1998. The results of active clinical follow up are also summarized in Table 1.

B) Modification of study protocol and plan of work

The experience of the first 2 years of field activity indicates that a screening program by PE can attain high coverage in this urban population. The positivity rate (3.0%) is sufficiently low to make this type of intervention costeffective provided that the positive predictive value and sensitivity of the test prove to be high. At present, the positive predictive value of the screening test appears rather low but a definitive value will be available only when all incident cases will be identified and linked to the cohort. Sensitivity will be estimated eventually by comparing the incidence of interval cancers (not detected by screening) in the intervention group, with the incidence in the control group. The cancer registries will provide these data.

Revision of study protocol.

In October 1997 we submitted a revision of the study protocol which was accepted by the US Army Medical Research Command. The revision of the study concerns essentially discontinuation of the intervention after completion of the first round and undertaking of follow up of the target population. This will provide information on the effectiveness of the prevalent screen (incidence and mortality rates in the two groups), as well as identifying the risk factors for breast and other female cancers in this population. No analytical study has ever been conducted to explain the relatively high incidence of breast cancer in this population. The information collected by interview at time of the intervention will allow us to quantify the excess incidence attributable to known risk factors.

The cohorts (intervention and control) will be followed for up to 10 years to study the onset of breast cancer and resulting mortality in relation to screening. The association between reproductive factors and cancer of the breast has never been studied in a prospective study of this size in a population with fertility rates characteristic of developing countries but showing patterns of cancer risk guite high for Asian standards. Other cancer sites, which will be related to reproductive factors, tobacco smoking, alcohol consumption and family history of cancer are cervix, ovary, corpus uteri, colon, lung, kidney and gallbladder. Cancers of the kidney and gallbladder have been associated with parity in women however, being rather rare cancer sites, the association has been investigated only in small studies. Details on this aspect of the study are given in the protocol revision and previous annual reports.

Second attempt to improve compliance of positive women with clinical follow-up.

Forty-three percent of the 3,472 women detected positive for a lump at 1st examination, refused biopsy and further clinical investigations. A second attempt to motivate these women towards diagnosis and treatment if required, has been performed in year 2000. Seventy of the positive women, who complied with clinical examination by a doctors

but refused biopsy were contacted by nurses and offered a second examination by a doctor. The visits took place in the Health Centers of the women's residence.

The results are shown in table 4. Four malignant cancers were detected (detection rate is 6%); 17 resulted negative for a lump at palpation, 10 (14%) had fibrocystic disease; 19 needed re-examination and 21 (30%) were lost to follow-up.

C) Follow-up phase.

The follow-up of the intervention and control cohorts consists in identifying women who develop breast cancer and/or other cancers, those who die from other causes and those who migrate outside the study area. The databases are continuously updated and data analyses are performed at fixed "closing dates".

Years 1998 and 1999 were devoted to the completion of databases from the intervention phase, clinical follow-up and management of women positive for a lump and the development of follow-up procedures. In addition, the collection of interview data on the prevalence of risk factors for breast cancer in women resident in the control areas was completed in 2000. In year 2000, the project entered the phase of routine follow up.

C.1 Procedures.

Procedures to computerize the data collected on incident cases and death certificates have been established and regular data entry ensures the maintenance of these databases. Data entered are subject to systematic checks for errors of coding and typing and for inconsistencies in the information recorded.

Follow-up procedures to match the master file and lists of the eligible populations (intervention and control cohorts) with the files of newly diagnosed cases and death certificates have been developed and tested. This takes advantage of a software program developed in Lyons for the purpose of identifying records pertaining to the same woman. The program makes use of the usual basic demographic items - names and surname, date of birth, age and detailed address - and allows for differences in spelling, or variations in the reported date of birth. Each variable contributing to the matching process is assigned a weight, which summarizes its discriminating power and the likelihood that it is reported incorrectly. The resulting matching score allows linkage of records within the same file (e.g. two screens of the same woman) or in different files.

D) October 2000 - September 2001 achievements.

Table 2 lists the type and amount of data collected so far.

D.2 On-going activities.

D.2.1 Continuing identification and recording of new breast cancer cases diagnosed in the resident population. The identification of incident cases in years 1995-1998 has been completed. We estimate that incidence data collected for year 1999 are 87% complete while year 2000 data include less than 50% of the expected cases. The distribution of 3,156 new cases diagnosed in 1995-2000 by stage at diagnosis is shown in Table 5. The data are tabulated by year of incidence for the intervention period, 1995-1997, and the following years. In the previous report we observed a small reduction of advanced stages in the first two years after the intervention. This is not confirmed in the present analysis with complete data. A positive remark is the reduction of cases of undetermined stage in the second period.

D.2.2 Continuing collection of death certificates (all causes) of women aged 30+ and resident in Metro Manila. About 15,000 records have been computerized.

D.2.3 Follow-up to assess vital status of intervention and control cohorts.

The file of death certificates is matched with the files of intervention and control population lists to identify women who died in the period. Unmatched women include those alive and resident but also some who migrated or died outside the area of Metro Manila. Active follow-up of this subgroup of the cohorts has to be performed at regular intervals.

A pilot study to assess compliance with mailed questionnaires is on-going.

D.2.4 Analysis of risk factors for breast cancer in the female population of Manila

The file of the breast cancer case register have been linked with the file of the intervention cohort and led to the identification of 169 cases. By comparing the date of diagnosis of cancer with the date when the participant was interviewed we identified 46 prevalent cases that were excluded from subsequent analyses. For each of the remaining 123 cases, eight controls were randomly selected from among all women in the cohort having the same age (+ 2 years), date of interview and PE (+ 4 months) and municipality of residence. Vital status of cases and controls is being assessed. Those traced and alive will be re-interviewed, proxies will be approached otherwise. In addition to assess vital status the scope is to update the information on reproductive factors that may well have changed since first recruitment, in this population characterized by high fertility.

We have conducted an analysis of the association between socio-demographic and reproductive variables and the risk of breast cancer, based on interviews collected at recruitment. The association between the factors analyzed and the risk of developing breast cancer is expressed by the relative risk (RR) estimated by conditional logistic regression for matched data. Ninety-five percent confidence limits (95% cl) express statistical significance of the RRs. The results are shown in Table 6.

There is no association between breast cancer and socio-economic level expressed by the average income per family member. On the contrary we observe a strong association with fertility: the incidence of breast cancer is 3 times greater in women with no children compared with women with 6 or more full-time pregnancies (RR=3.3, 95%cl 1.6-6.7). Their risk is even greater when compared with women who had their first child before age 19 (RR=4.8, 95%cl 1.8-13.2). We also observe clear dose-response relationships between parity and age at first child. These results are in agreement with the literature. The associations reported are particularly strong.

(6) KEY RESEARCH ACCOMPLISHMENTS

- Impact of the intervention by PE on mortality from breast cancer.
- Risk of cancer of breast, colon, rectum, gallbladder, kidney, cervix and corpus uteri, ovary and thyroid in relation to several characteristics of women's reproductive life, obesity, height, alcohol consumption, family history of breast cancer and tobacco smoking.
- Prevalence of risk factors for breast cancer in the female population of Metro Manila.
- The same factors above plus education and socio-economical level as determinants of stage at diagnosis of breast cancer and survival, taking account of treatment received.
- All-causes mortality in women according to alcohol consumption, adjusting for social class and other factors.
- Determinants of compliance with early diagnosis and treatment in a developing country.
- Sensitivity of PE performed by trained nurses compared with doctors.

(7) REPORTABLE OUTCOMES

- Poster presentation at the Era of Hope Conference, Washington D.C., 1-4 October 1997.
- Poster presentation at the Era of Hope Conference, Atlanta, 8-11 June 2000.
- REC-LINK software program for automatic matching of records based on personal id-items (e.g. name, surname, age, date of birth, address).
- Data base of the female population resident in Metro Manila in years 1995-1996.
- Data base of new cancer cases diagnosed in the resident population 1990-1999.
- Data base of incident breast cancer cases, years 1995-2000, with clinical details of stage at diagnosis and initial treatment.
- Data base of mortality in resident women (all causes).

(8) CONCLUSIONS

The program as a whole is not expected to reduce mortality from breast cancer in this population due to the low compliance with clinical investigation and treatment of women found positive at PE. All remedies put in place to overcome, at least, logistical problems linked to referral failed to improve the compliance.

A small shift in the distribution of stage at diagnosis towards earlier disease has been observed in cases diagnosed in the years when the intervention was carried out. Whether this is the result of the intervention is too early to tell but could be an indication of a potential positive impact of PE if accompanied by appropriate treatment. After one additional year of follow up the shift seems to persist.

During the first year of follow-up, the cancer registries have identified breast cancer cases presenting with advanced disease, who were positive at PE and refused further investigation one-two years earlier. This suggests that a small breast lump, which does not cause distress, is not perceived as something threatening one's health; it is only when the disease affects other organs that the woman seeks medical attention. This indicates that priority should be given to information and education of the population on the potential benefit of early detection. A better understanding of the cultural determinants of the attitude of this population towards health practices would help the Department of Health in developing future strategies.

The cohorts will be followed up for 5-10 years to study the onset of breast, other cancers and resulting mortality in relation to screening and to the data collected at interview during the initial examination.

The association between reproductive factors and cancer of the breast has never been studied in a prospective study of this size in a population with fertility rates characteristic of developing countries but showing patterns of cancer risk quite high for Asian standards. Cancers of the kidney and gallbladder are associated with parity and obesity in women however being rather rare cancers the association has been investigated only in small studies. The cohort of this study offers therefore a unique opportunity to test the association.

Table 1. Results of the single round screening, completed in December 1997.

Intervention No. interviewed	450,000		
	153,869		
No. interviewed and examined	147,558		
Compliance		96%	
Women detected positive			
Number of women detected positive and referred to tumor clinics	3,492		
positivity rate:		2.4%	
No. referred who completed the diagnostic process:	1,110		
percent compliance (includes women visited at home):		31.8%	
of which, No. referred who did not attend clinic and were visited at home	631		
No. with final diagnosis among women visited at home:	585	93.7%	
Outcome of diagnoses (3,492 women):			
no mass	545	15.6%	
malignant breast cancer:	33	0.9%	
benign breast disease:	532	15.2%	
actively refused further investigation (at clinics or home visits):	1,476	42.3%	
attended other clinic:	73	2.1%	
pending diagnoses:	71	2.0%	
not traced at initial address or died:	762	21.8%	

<u>Table 2</u>. Description and size of the databases completed as a result of the intervention and of those maintained for the follow-up of the cohorts.

Intervention:

	File	Content	No. of records
	Master file	Nominal list of all women interviewed and offered PE.	153,869
		Includes 10% who refused PE	
	Referrals	Nominal list of all women detected positive at 1 st PE by nurses. This file contains also the details of clinical follow up and final diagnosis.	3,492
	Intervention population lists	Lists of the eligible population resident in the intervention HCs in the years when the intervention was conducted.	218,928
	Control population lists	Lists of the eligible population resident in the control HCs in the years when the intervention was conducted.	191,086
	Repeated exams	Outcome of two examinations performed a year apart in a subgroup of the intervention cohort.	3,000
	Control interviews	Interviews of a sample of 1,000 women resident in control HCs. (On-going)	999
Follo	w-up, performed b	y the two cancer registries:	
Bre	east cancer cases	Detailed information on diagnoses (date, base and morphology if available), stage and survival of all new breast cancer cases diagnosed in Metro Manila.	3,300
De	eath Certificates	File of all deaths occurring in the resident population (women, age 30+), all causes.	15,000
All	cancer cases	Basic information on diagnosis and survival of all malignant cancer cases diagnosed in the resident population. Females.	years 1995-1999 7,000
inte	cident cases in the ervention and ntrol populations	Breast cancer cases diagnosed among the women who were examined in the intervention areas or in the cohort of women	169

Table 3 Comparison of characteristics of women who refused examination and of those who accepted.

	compliers	refusers	control sample
	N=92,091	N=12,404	N=999
age in years (mean±SD)	44.9±8.3	44.9±8.6	46.6 <u>+</u> 8.0
mean age at menarche	13.7±1.7	13.6±1.6	13.0 <u>+</u> 1.4
mean age at first fullterm pregnancy	23.2±4.6	23.9±4.9	21.6 <u>+</u> 3.8
ever used contraception (%) nulliparous (%) never had a PAP smear (%)	33.0%	26.9%	19.8%
	9.7%	15.7%	4%
	70.6%	71.0%	74.9%
smokers (%)	8.2%	7.5%	5.0%
drinkers (%)	7.7%	12.5%	26.3%

Table 4

Outcome of second attempt to follow-up clinically 70 women positive at PE who complied with one visit but refused further investigation.

Outcome	No. of women	
Lost to FU, moved to other province	21	
No mass at clinical examination	17	
Mass confirmed, fine needle biops	y offered:	
refused	2	
malignant cancer	4	
fibrocystic disease	10	
smear inadequate for evaluation	19	

Table 5 Relative frequency of stage at diagnosis of 1,700 incident cases by year of incidence, out of a total of 3,156 new cases identified. Stage is defined according to the American Joint Committee on Cancer and UICC/TNM classification systems.

	stage undetermined	<iib iib+<="" th=""><th>all defined stage</th></iib>		all defined stage
1995-1997	895	29.5	70.5	997
1998-1999	353	29.7	70.3	703

Table 6. Numbers of cases and controls, odds ratios (RR) and 95% confidence limits by levels of risk factors.

Factor	No. cases	No. controls	RR-a	95% c.l.
Family income (*):				
<667 §	25	223	1.	
667-	26	185	1.3	0.7-2.3
1167-	22	190	1.0	0.6-2.0
1875+	28	205	1.2	0.6-2.4
Unknwon	22	176	1.1	0.6-2.1
Age at menarche (years):				
<12	11	71	1.3	0.6-2.8
12-	27	182	1.3	0.7-2.2
13-	52	438	1.0	0.6-1.7
15+ §	32	276	1.	
Unknwon	1	11	8.0	0.1-6.3
No. of full-term pregnancies:				
Nulliparous	25	115	3.3	1.6-6.7
1-2	30	161	2.7	1.4-5.4
3	16	161	1.4	0.7-3.1
4-5	23	244	1.3	0.6-2.6
6+ §	14	193	1.	
unknown	15	104	2.2	0.9-5.0
Age at first pregnancy (years):				
<19 §	79	420	1.	
19-21	5	105	1.5	0.5-4.5
21-24	10	141	2.1	0.8-5.7
25+	22	220	3.7	1.5-9.6
nulliparous	25	115	4.8	1.8-13.2
unknown	7	92	0.9	0.2-3.9
Age at menopause (years):				
<45§	6	64	1.	
45-47	12	65	2.0	0.7-5.6
48-50	5	61	1.0	0.3-3.4
50+	18	97	2.3	0.8-6.3
Premenopausal & unknown	82	691	1.1	0.5-2.8

(*) Average annual income per family cohabitant in Pesos. § Reference category for the OR. RR-a: RRs adjusted for age and residential area. RR-b: RRs adjusted for age and residential area and mutually adjusted for each other.

(9) REFERENCES

Barnum, H. and Greenberg, R. (1991) Health Sector Priorities Review. Cancer. The World Bank, Washington, D.C.

Coleman, M.P., Estève, J., Damiecki, P., Arslan, A. and Renard. H. (1993) Trends in Cancer Incidence and Mortality (IARC Scientific Publications No. 121), Lyon, International Agency for Research on Cancer.

Day, N.E. (1991) Screening for Breast Cancer. Brit Med Bull 47, 400-415.

Ferlay J., Parkin D.M., Pisani P., GLOBOCAN 1, IARC Cancer Base No.3, 1998, IARC, Lyons.

Miller, A. B., Chamberlain, J., Day, N.E., Hakama, M. and Prorok, P.C. (1990). Report on a workshop of the UICC project on evaluation of screening for cancer. Int J Cancer **46**, 761-769.

Moss, S.E. (1996) Advances in screening for breast cancer. In: A.B. Miller (ed.) Advances in cancer screening. Kluwer Academic Publishers, Norwell, USA.

Nab H.W., Hop W.C.J., Crommelin M.A., Kluck H.M., van der Heijden L.H., Coebergh JW.W. (1994) Changes in long term prognosis for breast cancer in a Dutch cancer registry. Br. Med.J. **309**, 83-86.

Nelson N.J. (1997) The mammography consensus jury speaks out. J.Natl. Cancer Inst. 89,344-347.

Olivotto I.A., Bajdik C.D., Plenderleith I.H., Coppin C.M., Gelmon K.A., Jackson S.M., Ragaz J., Wilson K. S., Worth A. (1994) Adjuvant systemic therapy and survival after breast cancer. N. Engl. J. Med. 330, 805-810.

Pisani P, Parkin D.M., Muñoz N., Ferlay J. (1997) Cancer and infection, estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomarkers & Prev.

Thomas B.D., Gao D.L., Self S.G., Allison C.J., Tao Y., Mahloch J., Ray R., Qin Q., Presley R., Porter P. (1997) Randomized trial of breast self-examination in Shangai: methodology and preliminary results. J.Natl. Cancer Inst. **89**, 355-365.

WHO (1984) Self-examination in the early detection of breast cancer: memorandum from a WHO meeting. Bull WHO **62**, 861-869,